Market Cap 1.76B
Revenue (ttm) 0.00
Net Income (ttm) -89.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 976,741
Avg Vol 1,052,522
Day's Range N/A - N/A
Shares Out 59.80M
Stochastic %K 68%
Beta 0.33
Analysts Strong Sell
Price Target $40.62

Company Profile

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatm...

Industry: Biotechnology
Sector: Healthcare
Phone: 720 647 8519
Address:
6200 Lookout Road, Boulder, United States
GRASSFEDBEEF
GRASSFEDBEEF Mar. 5 at 2:20 PM
$ELVN The Enliven Therapeutics, Inc. stock price gained 4.28% on the last trading day (Wednesday, 4th Mar 2026), rising from $28.75 to $29.98. During the last trading day the stock fluctuated 9.01% from a day low at $27.97 to a day high of $30.49. The price has risen in 6 of the last 10 days and is up by 13.69% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 237 thousand more shares were traded than the day before. In total, 895 thousand shares were bought and sold for approximately $26.82 million. The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 66.11% during the next 3 months and, with a 90% probability hold a price between $40.98 and $60.18 at the end of this 3-month period.
0 · Reply
d_risk
d_risk Mar. 3 at 9:53 PM
$ELVN - Enliven Therapeutics Inc - 10K - Updated Risk Factors ELVN’s 10-K sharpens risk around a single lead asset ELVN-001 (dropping ELVN-002 and licensing as core dependencies), adds FDA design/interpretation and companion diagnostic hurdles, introduces fresh going-concern-style and public-company burden risks, and broadens detail on team dependence, cyber/data, global ops, third parties, market volatility, and operational disruptions. #Biopharmaceuticals #DrugDevelopmentRisks #FDARegulatory #GoingConcern #Cybersecurity 🟢 Added 🟠 Removed https://d-risk.ai/ELVN/10-K/2026-03-03
0 · Reply
StockConsultant
StockConsultant Feb. 24 at 12:00 AM
$ELVN Enliven Therapeutics stock, nice setup and rally off the 25.85 triple support area, from Stocks to Watch at https://stockconsultant.com/?ELVN
0 · Reply
Sambong
Sambong Feb. 19 at 6:37 AM
$ELVN play safe ..over 30. ER on 3/12
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 12 at 6:51 PM
$ELVN RSI: 57.28, MACD: 1.6420 Vol: 1.10, MA20: 26.99, MA50: 22.12 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
thedentite
thedentite Feb. 6 at 6:46 PM
$ELVN Well will you look at that! What a great day
0 · Reply
DispersionX
DispersionX Feb. 4 at 1:49 PM
$ELVN is a clinical-stage biotech developing kinase inhibitors for inflammatory diseases; its lead candidate shows potential, but it is early in development with significant competition ahead.
0 · Reply
BobBobbertonnn
BobBobbertonnn Feb. 2 at 9:18 PM
1 · Reply
thedentite
thedentite Feb. 2 at 8:06 PM
$ELVN Another great day. What's not to like?
0 · Reply
thedentite
thedentite Feb. 1 at 12:52 AM
$ELVN This company is going places.
0 · Reply
Latest News on ELVN
Enliven Therapeutics to Present at Upcoming Investor Conferences

May 22, 2025, 4:05 PM EDT - 10 months ago

Enliven Therapeutics to Present at Upcoming Investor Conferences


Final Trade: CVX, XLE, ELVN, COF

Mar 21, 2025, 6:38 PM EDT - 1 year ago

Final Trade: CVX, XLE, ELVN, COF

CVX XLE COF


Enliven's Early Data Stands Out From Peers

Jan 7, 2025, 12:28 AM EST - 1 year ago

Enliven's Early Data Stands Out From Peers


Why Enliven is this analyst's top biotech stock pick

Oct 18, 2024, 7:18 PM EDT - 1 year ago

Why Enliven is this analyst's top biotech stock pick


Imara Announces Stockholder Approval of Merger With Enliven

Feb 22, 2023, 4:01 PM EST - 3 years ago

Imara Announces Stockholder Approval of Merger With Enliven


Enliven Therapeutics and Imara Announce Merger Agreement

Oct 13, 2022, 4:35 PM EDT - 3 years ago

Enliven Therapeutics and Imara Announce Merger Agreement


Imara: Potential Liquidation

Sep 29, 2022, 3:06 PM EDT - 3 years ago

Imara: Potential Liquidation


Read Why Imara Shares Are Falling Today

Apr 5, 2022, 10:13 AM EDT - 4 years ago

Read Why Imara Shares Are Falling Today


Imara To Start Testing Tovinontrine In Heart Failure Patients

Jan 25, 2022, 11:03 AM EST - 4 years ago

Imara To Start Testing Tovinontrine In Heart Failure Patients


GRASSFEDBEEF
GRASSFEDBEEF Mar. 5 at 2:20 PM
$ELVN The Enliven Therapeutics, Inc. stock price gained 4.28% on the last trading day (Wednesday, 4th Mar 2026), rising from $28.75 to $29.98. During the last trading day the stock fluctuated 9.01% from a day low at $27.97 to a day high of $30.49. The price has risen in 6 of the last 10 days and is up by 13.69% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 237 thousand more shares were traded than the day before. In total, 895 thousand shares were bought and sold for approximately $26.82 million. The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 66.11% during the next 3 months and, with a 90% probability hold a price between $40.98 and $60.18 at the end of this 3-month period.
0 · Reply
d_risk
d_risk Mar. 3 at 9:53 PM
$ELVN - Enliven Therapeutics Inc - 10K - Updated Risk Factors ELVN’s 10-K sharpens risk around a single lead asset ELVN-001 (dropping ELVN-002 and licensing as core dependencies), adds FDA design/interpretation and companion diagnostic hurdles, introduces fresh going-concern-style and public-company burden risks, and broadens detail on team dependence, cyber/data, global ops, third parties, market volatility, and operational disruptions. #Biopharmaceuticals #DrugDevelopmentRisks #FDARegulatory #GoingConcern #Cybersecurity 🟢 Added 🟠 Removed https://d-risk.ai/ELVN/10-K/2026-03-03
0 · Reply
StockConsultant
StockConsultant Feb. 24 at 12:00 AM
$ELVN Enliven Therapeutics stock, nice setup and rally off the 25.85 triple support area, from Stocks to Watch at https://stockconsultant.com/?ELVN
0 · Reply
Sambong
Sambong Feb. 19 at 6:37 AM
$ELVN play safe ..over 30. ER on 3/12
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 12 at 6:51 PM
$ELVN RSI: 57.28, MACD: 1.6420 Vol: 1.10, MA20: 26.99, MA50: 22.12 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
thedentite
thedentite Feb. 6 at 6:46 PM
$ELVN Well will you look at that! What a great day
0 · Reply
DispersionX
DispersionX Feb. 4 at 1:49 PM
$ELVN is a clinical-stage biotech developing kinase inhibitors for inflammatory diseases; its lead candidate shows potential, but it is early in development with significant competition ahead.
0 · Reply
BobBobbertonnn
BobBobbertonnn Feb. 2 at 9:18 PM
1 · Reply
thedentite
thedentite Feb. 2 at 8:06 PM
$ELVN Another great day. What's not to like?
0 · Reply
thedentite
thedentite Feb. 1 at 12:52 AM
$ELVN This company is going places.
0 · Reply
justiceforb_85
justiceforb_85 Jan. 28 at 2:59 AM
$ELVN remains undervalued.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 23 at 3:37 AM
$ELVN RSI: 85.29, MACD: 2.3782 Vol: 5.28, MA20: 20.85, MA50: 20.33 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Sw1ngb0t
Sw1ngb0t Jan. 23 at 1:10 AM
0 · Reply
thedentite
thedentite Jan. 22 at 3:14 PM
$ELVN Big green candle. Nice
0 · Reply
thedentite
thedentite Jan. 21 at 6:41 PM
$ELVN I love the gentle movement up.
1 · Reply
thedentite
thedentite Jan. 16 at 6:38 PM
$ELVN Bearish sentiment? Ha
1 · Reply
blue81
blue81 Jan. 16 at 6:52 AM
$ELVN 33$ is coming in this quarter
0 · Reply
Jimbates22
Jimbates22 Jan. 14 at 6:45 PM
$ELVN green to red. A sign that the pump is over.
0 · Reply
Jimbates22
Jimbates22 Jan. 14 at 5:51 PM
$ELVN looks like they are setting up for an offering. Insiders dumping
1 · Reply
johnmidland
johnmidland Jan. 14 at 3:50 PM
$ELVN so all the insiders are dumping their shares hand over fist and we are somehow holding $26? SMH
1 · Reply
Quantumup
Quantumup Jan. 13 at 8:45 PM
William Blair reiterated $TERN Outperform/Top Pick. $NVS $ELVN William Blair said in its note: Following the company's presentation last year at the American Society of Hematology (ASH) annual meeting, it is our view that "unprecedented" remains the only suitable adjective to describe the clinical activity of TERN-701 in third-line or later chronic myeloid leukemia (CML). It is rare for an investigational agent to demonstrate unequivocal improvement in both clinical efficacy and safety and concurrently provide patients with better convenience of daily dosing with no food effect. William Blair went on to say: https://x.com/Quantumup1/status/2011175547691548887?s=20
0 · Reply
thedentite
thedentite Jan. 13 at 4:08 PM
$ELVN Back in the right direction. I see a bright future
0 · Reply